[Treatment of certain refractory arterial hypertensions with a monoamine oxidase inhibitor].

Sixteen patients with refractory hypertension were treated with the monoamine oxidase inhibitor iproclozide at doses of 10 to 30 mg/day. Its addition to the previously prescribed antihypertensive therapy resulted in normalisation of blood pressure readings in two cases, significant improvement in seven cases and no change in four cases. Side effects due to iproclozide were relatively minor, the treatment having to be discontinued in three cases. Its association with alpha methyldopa or spironolactone did not lead to any untoward complications. Despite the success of other recently introduced drugs in refractory hypertension, this study shows that MAOI may be very useful in the management of this condition.
AuthorsM Colliard, A Michelet, P Tcherdakoff
JournalArchives des maladies du coeur et des vaisseaux (Arch Mal Coeur Vaiss) Vol. 74 Spec No Pg. 99-106 (Jun 1981) ISSN: 0003-9683 [Print] FRANCE
Vernacular TitleTraitement de certaines hypertensions artérielles réfractaires par un inhibiteur de la mono-amino-oxydase.
PMID6794533 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Glycolates
  • Hydrazines
  • Monoamine Oxidase Inhibitors
  • iproclozide
  • Female
  • Glycolates (therapeutic use)
  • Humans
  • Hydrazines (therapeutic use)
  • Hypertension (drug therapy)
  • Male
  • Monoamine Oxidase Inhibitors (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: